Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
LXO Group hybrid capital acquisition financing
We advised Hayfin Capital Management on its hybrid capital investment in LXO Group
AbelZeta sale of China rights to GPC3 CAR-T therapy to AstraZeneca
We advised AbelZeta on the transaction
Penumbra $14.5 billion sale to Boston Scientific
We are advising Penumbra on the transaction
Roche Holdings $1.9 billion notes offering
We advised Roche on the offering comprising three tranches of notes
bit.bio $50 million Series C equity financing
We are advising the company on the funding round
Aktis Oncology $318 million IPO
This is the first biotech IPO of 2026
Beacon Therapeutics $75 million Series C financing round
We advised Forbion on its participation in the financing round
W. L. Gore & Associates acquisition of Conformal Medical
We are advising Gore on the transaction
InSilico Medicine HK$2.62 billion IPO
We advised InSilico Medicine on its IPO and HKEX listing
PegBio HK$300 million placement of shares
We advised PegBio on the placement of new shares